Pharma feed

Amgen, Inc.
Bit (ly)· 25 May 2019

Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm

What’s a pharma company to do when another drugmaker poaches 19 of its salespeople in preparation for launching a rival product? Many companies would buckle down, hire even more qualified salespeople and prop up the marketing message to make it clear to physicians why they should choose the first-to-market product.

  • Amgen, Inc.
  • Bitly Inc
  • Competitive Landscape
  • New Offerings
  • Company Websites
Novartis AG
Novartis· 25 May 2019

FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone in the SOLAR-1 clinical trial[1],[2],[3],[4] ~40% of

  • Novartis AG
  • Regulatory and Legal
  • Press Releases
  • Company Websites
N
Novartis AG
Genomeweb· 25 May 2019

FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Qiagen's Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis' alpelisib (Piqray).

  • COMPanion Corporation
  • Novartis AG
  • Qiagen GmbH
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Nbonews· 25 May 2019

As Merck & Co (MRK) Shares Rose, Excalibur Management Trimmed Position by $617,348; Paragon Capital Management Has Trimmed Its Position in Caseys Gen Stores (CASY) by $639,488

Paragon Capital Management Llc decreased its stake in Caseys Gen Stores (CASY) by 7.2% based on its latest 2018Q4 regulatory filing with the SEC. Paragon Capital Management Llc sold 4,996 shares as the company’s stock rose 3.93% with the market.

  • Paragon Capital Management LLC
  • Merck & Co., Inc.
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 25 May 2019

FDA OKs Novartis' alpelisib for certain type of breast cancer; shares up 4%

The FDA approves Novartis' (NVS +3.7% ) Piqray (alpelisib), a PI3K inhibitor, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA-mutated advanced or metastatic breast cancer in patients who have progressed after receiving endocrine-based therapy.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 25 May 2019

Novartis' PI3K inhibitor Piqray authorised by FDA for certain patients with advanced breast cancer

Novartis on Friday announced the approval of Piqray (alpelisib) for use in combination with AstraZeneca's endocrine therapy Faslodex (fulvestrant) to treat postmenopausal women, as well as men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Diligent
Nbonews· 25 May 2019

As Merck & Co (MRK) Share Price Rose, Diligent Investors Trimmed Its Position by $693,728; Clough Capital Partners LP Increases Holding in Golub Cap Bdc (GBDC)

Diligent Investors Llc decreased its stake in Merck & Co Inc (MRK) by 33.35% based on its latest 2018Q4 regulatory filing with the SEC. Diligent Investors Llc sold 9,128 shares as the company’s stock rose 5.36% with the market.

  • Diligent
  • Golub Group Equity Fund
  • Merck & Co., Inc.
  • Clough Capital Partners LP
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Cryptocoinstribune· 25 May 2019

Connors Investor Services Has Raised Merck (MRK) Position; Whitebox Advisors Has Lifted Its Ryder Sys (R) Holding

Connors Investor Services Inc increased Merck (MRK) stake by 76.48% reported in 2018Q4 SEC filing. Connors Investor Services Inc acquired 66,790 shares as Merck (MRK)’s stock rose 5.36%. The Connors Investor Services Inc holds 154,117 shares with $11.78 million value, up from 87,327 last quarter.

  • Merck & Co., Inc.
  • Connors Investor Services Inc
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
BharataPress· 25 May 2019

The Wells Trecaso Financial Group LLC Acquires 3,615 Shares of Merck & Co., Inc. (MRK) – BharataPress

Wells Trecaso Financial Group LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 79.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,155 shares of the company’s stock after purchasing an additional 3,615 shares during the quarter.

  • Merck & Co., Inc.
  • SSQ Insurance
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Techknowbits· 25 May 2019

47,795 Shares in Merck & Co., Inc. (MRK) Purchased by Lehman & Derafelo Financial Resources LLC

Lehman & Derafelo Financial Resources LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.

  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Legal & General Group PLC
Techknowbits· 25 May 2019

Legal & General Group Plc Raises Holdings in AbbVie Inc (ABBV)

Legal & General Group Plc boosted its position in shares of AbbVie Inc (NYSE:ABBV) by 7.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 7,386,397 shares of the company’s stock after acquiring an additional 490,348 shares during the quarter.

  • Legal & General Group PLC
  • AbbVie Inc
  • M&A Activities
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Mylan Specialty LP
Sundance Herald· 25 May 2019

Head-To-Head Review: Mylan (MYL) versus Merck & Co., Inc. (MRK)

Merck & Co., Inc. (NYSE:MRK) and Mylan (NASDAQ:MYL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.

  • Mylan Specialty LP
  • Merck & Co., Inc.
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Techknowbits· 25 May 2019

Dana Investment Advisors Inc. Takes $7.71 Million Position in Merck & Co., Inc. (MRK)

Dana Investment Advisors Inc. acquired a new stake in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 100,904 shares of the company’s stock, valued at approximately $7,710,000.

  • Merck & Co., Inc.
  • Dana Investment Advisors Inc
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Novartis AG
Arkansas Online · 25 May 2019

FDA approves $2.1M drug for baby disease

This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $2.125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Sundance Herald· 25 May 2019

Mackay Shields LLC Has $51.98 Million Stake in Merck & Co., Inc. (MRK)

Mackay Shields LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 24.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 680,277 shares of the company’s stock after acquiring an additional 135,042 shares during the period.

  • MacKay Shields LLC
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Biogen Inc
Sundance Herald· 25 May 2019

Court Place Advisors LLC Boosts Holdings in Biogen Inc (NASDAQ:BIIB)

Court Place Advisors LLC increased its holdings in Biogen Inc (NASDAQ:BIIB) by 3.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,684 shares of the biotechnology company’s stock after acquiring an additional 540 shares during the quarter.

  • Biogen Inc
  • M&A Activities
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Rockland Register· 25 May 2019

Berman Capital Advisors LLC Acquires 4,178 Shares of Merck & Co., Inc. (MRK)

Berman Capital Advisors LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 79.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,411 shares of the company’s stock after acquiring an additional 4,178 shares during the quarter.

  • Berman Capital Advisors LLC
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Mayfieldrecorder· 25 May 2019

Merck & Co., Inc. (MRK) Position Lifted by Lido Advisors LLC

Lido Advisors LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 67.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,710 shares of the company’s stock after acquiring an additional 7,963 shares during the quarter.

  • Lido Advisors Inc
  • Merck & Co., Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Sanofi
Cryptocoinstribune· 24 May 2019

Sanofi Sponsor (SNY) Shares Declined While Cutler Capital Management Has Cut by $481,600 Its Stake; Speece Thorson Capital Group Position in Mueller Wtr Prods (MWA) Has Raised by $2.06 Million as Valu

Speece Thorson Capital Group Inc increased its stake in Mueller Wtr Prods Inc (MWA) by 25.99% based on its latest 2018Q4 regulatory filing with the SEC. Speece Thorson Capital Group Inc bought 228,519 shares as the company’s stock declined 0.76% while stock markets rallied.

  • Cutler Capital Management LLC
  • Speece Thorson Capital Group Inc
  • Sanofi
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 24 May 2019

Novartis' PI3K inhibitor Piqray authorised by FDA for certain patients with advanced breast cancer

Novartis on Friday announced the approval of Piqray (alpelisib) for use in combination with AstraZeneca's endocrine therapy Faslodex (fulvestrant) to treat postmenopausal women, as well as men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Ionis Pharmaceuticals
Seeking Alpha· 24 May 2019

Ionis down 2% on FDA nod for Novartis gene therapy for SMA1

Ionis Pharmaceuticals (IONS -2.2% ) is under modest pressure on the heels of the FDA's OK of Novartis' gene therapy Zolgensma for spinal muscular atrophy Type 1 (SMA1). Ionis out-licensed nusinersen, branded as Spinraza, to Biogen.

  • Ionis Pharmaceuticals
  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Nbonews· 24 May 2019

Lourd Capital Has Cut Merck & Co (MRK) Stake by $492,708; Market Value Rose; As Fidelity National Financial (FNF) Market Valuation Rose, Price T Rowe Associates Increased Its Holding

Lourd Capital Llc decreased its stake in Merck & Co Inc (MRK) by 44.68% based on its latest 2018Q4 regulatory filing with the SEC. Lourd Capital Llc sold 6,483 shares as the company’s stock rose 5.36% with the market.

  • Rowe Associates Inc
  • Lourd Capital LLC
  • Merck & Co., Inc.
  • Fidelity National Financial Inc
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Enherald· 24 May 2019

Kentucky Retirement Systems Insurance Trust Fund Increased Johnson & Johnson (JNJ) Stake by $306,246; Realpage (RP) Holder Tygh Capital Management Lifted Its Holding

Tygh Capital Management Inc increased its stake in Realpage Inc (RP) by 12.94% based on its latest 2018Q4 regulatory filing with the SEC. Tygh Capital Management Inc bought 23,295 shares as the company’s stock rose 17.61% with the market.

  • Kentucky Retirement Systems
  • Johnson & Johnson
  • Tygh Capital Management
  • Funding Activities
  • News Articles
  • News and Other Websites
N
Sanofi
Chemdiv· 24 May 2019

Cegedim, Sanofi enter healthcare improvement RWD collaboration

Cegedim, Sanofi enter healthcare improvement RWD collaboration Cegedim has announced that it is set to engage in an innovative collaboration on Real World Data for healthcare improvement in Europe with Sanofi. The company has announced that it will provide Sanofi with information going back to 1994 for its full Real World dataset France & UK, powered by its proprietary THIN database.

  • CEGEDIM GROUP
  • Sanofi
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 24 May 2019

FDA OKs Novartis' Zolgensma for SMA1

The FDA has approved Novartis' (NVS +3.2% ) gene therapy Zolgensma (onsaemnogene abeparvovec-xioi) for the treatment of spinal muscular atrophy Type 1 (SMA1).

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
1 2 3 4 5